Navigation Links
Therapure Biopharma Inc. Signs Biomanufacturing Contract with Diamedica Incorporated
Date:6/30/2010

Therapure Biopharma Inc. today announced an agreement under which Therapure will provide development services for Diamedica Incorporated, a biopharmaceutical company based in Winnipeg, Manitoba. Under the terms of the agreement, Therapure will provide cell line development and protein production services to support clinical development for one of Diamedica’s products, a protein which may be used for the treatment of diabetes and neurological disorders. The companies are also negotiating contracts for on-going GMP manufacturing services. Financial terms were not disclosed.

Toronto, ON (Vocus) June 30, 2010 -- Therapure Biopharma Inc. today announced an agreement under which Therapure will provide development services for Diamedica Incorporated, a biopharmaceutical company based in Winnipeg, Manitoba. Under the terms of the agreement, Therapure will provide cell line development and protein production services to support clinical development for one of Diamedica’s products, a protein which may be used for the treatment of diabetes and neurological disorders. The companies are also negotiating contracts for on-going GMP manufacturing services. Financial terms were not disclosed.

DiaMedica Inc. (DiaMedica) is a Canada-based biopharmaceutical company focused on developing treatments for diseases with significant unmet need including diabetes and neurological diseases. The Company has been selected as one of Canada’s Top 10™ life science companies in 2007/2008 and 2008/2009 by the Ottawa Centre for Research and Innovation (OCRI) and has several compounds in various stages of development.

“We are proud to have been chosen by Diamedica as its partner to provide cell line development and protein production services” said Thomas Wellner, President and CEO of Therapure. “Therapure has performed similar services for a number of clients and has demonstrated market leading expertise,” continued Mr. Wellner.

'Diamedica was seeking a cell line developer with the scientific expertise to handle this specialty product,' said Rick Pauls, CEO of Diamedica Inc. 'This project is important to DiaMedica’s future success and we are confident in Therapure’s ability to meet our needs'.

About Therapure Biopharma Inc.:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market for its clients. Therapure’s Health Canada licensed 130,000 sq. ft. facility, includes manufacturing, research and quality control laboratories and a cGMP warehouse, and is built to U.S. FDA, EMEA, MHRA and Health Canada standards for the aseptic handling and purification of proteins.

For more information, please visit: www.therapurebio.com

# # #

Read the full story at http://www.prweb.com/releases/biopharma/manufacturing/prweb4204774.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Therapure Biopharma Inc. opens for business with first client contracts
2. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
3. Therapure Biopharma Inc. announces collaboration with BioVectra Inc.
4. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
5. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
6. Microbix And Therapure Biopharma Form Partnership To Expand Water-Based Supplies To The Pharma Industry
7. Therapure Biopharma Inc. Signs Biomanufacturing Contract with ProChon Biotech Ltd.
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Therapure Biopharma Inc. Signs Biomanufacturing Contract with Diamedica Incorporated
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... ... , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on August ... MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon ... awards honoring scientists who have made outstanding contributions to analytical chemistry ... Pittcon 2018, the world’s leading conference and exposition for laboratory science, which will ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
Breaking Biology News(10 mins):